PL2034999T3 - Estry DHA i ich zastosowanie w leczeniu i zapobieganiu chorobom sercowo-naczyniowym - Google Patents

Estry DHA i ich zastosowanie w leczeniu i zapobieganiu chorobom sercowo-naczyniowym

Info

Publication number
PL2034999T3
PL2034999T3 PL07765584T PL07765584T PL2034999T3 PL 2034999 T3 PL2034999 T3 PL 2034999T3 PL 07765584 T PL07765584 T PL 07765584T PL 07765584 T PL07765584 T PL 07765584T PL 2034999 T3 PL2034999 T3 PL 2034999T3
Authority
PL
Poland
Prior art keywords
prevention
treatment
cardiovascular diseases
dha esters
dha
Prior art date
Application number
PL07765584T
Other languages
English (en)
Inventor
Frédérique Brune
André Delhon
Jean Gardette
Jean François Patoiseau
Alain Marty
Etienne Severac
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2034999(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of PL2034999T3 publication Critical patent/PL2034999T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/02—Preparation of carboxylic acid esters by interreacting ester groups, i.e. transesterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL07765584T 2006-06-23 2007-06-22 Estry DHA i ich zastosowanie w leczeniu i zapobieganiu chorobom sercowo-naczyniowym PL2034999T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0605649A FR2902659A1 (fr) 2006-06-23 2006-06-23 Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
PCT/EP2007/056277 WO2007147899A2 (en) 2006-06-23 2007-06-22 Dha esters and use thereof in treatment and prevention of cardiovascular disease
EP07765584A EP2034999B9 (en) 2006-06-23 2007-06-22 Dha esters and use thereof in the treatment and the prevention of cardiovascular diseases

Publications (1)

Publication Number Publication Date
PL2034999T3 true PL2034999T3 (pl) 2011-05-31

Family

ID=37686083

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07765584T PL2034999T3 (pl) 2006-06-23 2007-06-22 Estry DHA i ich zastosowanie w leczeniu i zapobieganiu chorobom sercowo-naczyniowym

Country Status (38)

Country Link
US (2) US8034377B2 (pl)
EP (1) EP2034999B9 (pl)
JP (1) JP5053372B2 (pl)
KR (1) KR101380128B1 (pl)
CN (1) CN101472590A (pl)
AR (1) AR061622A1 (pl)
AT (1) ATE489091T1 (pl)
AU (1) AU2007262958B2 (pl)
BR (1) BRPI0713725A2 (pl)
CA (1) CA2655570C (pl)
CL (1) CL2010001123A1 (pl)
CO (1) CO6150156A2 (pl)
CR (1) CR10507A (pl)
DE (1) DE602007010776D1 (pl)
DK (1) DK2034999T3 (pl)
EC (1) ECSP099039A (pl)
ES (1) ES2355611T3 (pl)
FR (1) FR2902659A1 (pl)
GE (1) GEP20125464B (pl)
HN (1) HN2008001771A (pl)
HR (1) HRP20110086T1 (pl)
IL (1) IL195562A (pl)
MA (1) MA30584B1 (pl)
MX (1) MX2009000103A (pl)
MY (1) MY145985A (pl)
NO (1) NO20090334L (pl)
NZ (1) NZ573454A (pl)
PL (1) PL2034999T3 (pl)
PT (1) PT2034999E (pl)
RS (1) RS51629B (pl)
RU (1) RU2451672C2 (pl)
SA (1) SA07280345B1 (pl)
SI (1) SI2034999T1 (pl)
TN (1) TNSN08527A1 (pl)
TW (1) TWI389888B (pl)
UA (1) UA96156C2 (pl)
WO (1) WO2007147899A2 (pl)
ZA (1) ZA200900334B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334536B1 (es) * 2008-04-11 2011-01-24 Universidad Complutense De Madrid Procedimiento para la obtencion selectiva de 12-hidroxi-9-cis-octadecenoato de (1,4:3,6-dianhidro-d-glucitol) utilizando lipasas inmovilizadas como catalizador.
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
US20110311547A1 (en) * 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis Treatment
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
KR20130108305A (ko) 2010-08-23 2013-10-02 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN102757444B (zh) * 2011-04-29 2016-02-10 南京信诺泰医药有限公司 具有一氧化氮供体性质的苯并呋喃类化合物
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
WO2016024283A1 (en) * 2014-08-12 2016-02-18 Praj Industries Limited Process for the preparation of triglycerides of epa and dha
US10441087B2 (en) 2015-02-24 2019-10-15 Sleep Number Corporation Mattress with adjustable firmness
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
IL268804B2 (en) * 2017-02-20 2023-04-01 Univ Louisiana State Hydrogen sulfide and/or nitrite for the treatment and prevention of atrial fibrillation
CN110950881A (zh) * 2018-09-27 2020-04-03 中国科学院上海药物研究所 一类三环类似物、其制备方法和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL133049C (pl) 1966-02-24
JPS5967263A (ja) 1982-10-07 1984-04-16 Terumo Corp ペンタエン高級脂肪酸ピリジルアルコ−ルエステルおよびその製法
JPS5967264A (ja) 1982-10-08 1984-04-16 Terumo Corp 血小板凝集抑制剤
EP0125252A1 (de) * 1982-11-16 1984-11-21 MOTSCHAN, Georges Neue verwendung eines einzelnen vitamins oder einer kombination verschiedener vitamine
JPS6034947A (ja) * 1983-08-05 1985-02-22 Terumo Corp ドコサヘキサエン酸誘導体およびそれを用いた血小板凝集阻止剤
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
CA2220091C (en) 1995-05-01 2011-01-04 Scotia Holdings Plc Nicotinic acid esters and pharmaceutical compositions containing them
IL118092A0 (en) 1995-05-03 1996-09-12 Smithkline Beecham Plc Antibacterial compounds their preparation and pharmaceutical compositions containing them
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
WO2004091603A1 (fr) * 2003-04-07 2004-10-28 Clinigenetics Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
EP1466597A1 (en) * 2003-04-07 2004-10-13 Clinigenetics Use of dha esters to control or prevent cardiovascular diseases
AU2004229165A1 (en) 2003-04-17 2004-10-28 Pharmaton S.A. Multi-vitamin and mineral supplement for pregnant women

Also Published As

Publication number Publication date
EP2034999A2 (en) 2009-03-18
TW200811108A (en) 2008-03-01
MA30584B1 (fr) 2009-07-01
RU2008152248A (ru) 2010-07-27
NZ573454A (en) 2010-10-29
IL195562A0 (en) 2009-09-01
RU2451672C2 (ru) 2012-05-27
US8227479B2 (en) 2012-07-24
IL195562A (en) 2012-06-28
KR101380128B1 (ko) 2014-04-11
UA96156C2 (ru) 2011-10-10
HRP20110086T1 (hr) 2011-03-31
RS51629B (en) 2011-08-31
AU2007262958B2 (en) 2011-10-27
DE602007010776D1 (de) 2011-01-05
EP2034999B9 (en) 2011-03-09
MX2009000103A (es) 2009-01-23
SA07280345B1 (ar) 2011-01-15
CA2655570A1 (en) 2007-12-27
JP2009544576A (ja) 2009-12-17
SI2034999T1 (sl) 2011-02-28
WO2007147899B1 (en) 2008-05-02
WO2007147899A3 (en) 2008-03-13
ECSP099039A (es) 2009-02-27
CO6150156A2 (es) 2010-04-20
ZA200900334B (en) 2009-12-30
GEP20125464B (en) 2012-04-10
CA2655570C (en) 2015-09-08
JP5053372B2 (ja) 2012-10-17
ATE489091T1 (de) 2010-12-15
KR20090024794A (ko) 2009-03-09
US8034377B2 (en) 2011-10-11
EP2034999B1 (en) 2010-11-24
TWI389888B (zh) 2013-03-21
ES2355611T3 (es) 2011-03-29
US20110237613A1 (en) 2011-09-29
HN2008001771A (es) 2011-01-24
AU2007262958A1 (en) 2007-12-27
AR061622A1 (es) 2008-09-10
US20090312354A1 (en) 2009-12-17
TNSN08527A1 (en) 2010-04-14
CR10507A (es) 2009-02-05
FR2902659A1 (fr) 2007-12-28
BRPI0713725A2 (pt) 2012-10-30
CL2010001123A1 (es) 2011-03-25
DK2034999T3 (da) 2011-01-24
PT2034999E (pt) 2011-01-19
NO20090334L (no) 2009-03-04
WO2007147899A2 (en) 2007-12-27
CN101472590A (zh) 2009-07-01
MY145985A (en) 2012-05-31

Similar Documents

Publication Publication Date Title
PL2034999T3 (pl) Estry DHA i ich zastosowanie w leczeniu i zapobieganiu chorobom sercowo-naczyniowym
PL2546253T3 (pl) Podstawione dihydropirazolony do leczenia schorzeń sercowo-naczyniowych i hematologicznych
SI2118074T1 (sl) Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
EP1919468A4 (en) TREATMENT WITH CHOLESTEROL ABSORPTION INHIBITORS BASED ON AZETIDINONE AND OMEGA-3 FATTY ACID AND COMBINATION PRODUCT THEREOF
EP2007385A4 (en) CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
ZA200900051B (en) Modulators of metabolism and the treatment of disorders related thereto
IL195851A0 (en) Modulators of metabolism and the treatment of disorders related thereto
IL206080A0 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
EP2185202A4 (en) USE OF INTERLEUKIN-22 FOR THE TREATMENT OF FATTLEBER
HK1203482A1 (en) Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states pde4
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
EP2240193A4 (en) COMPOSITION COMPRISING LINDERA OBTUSILOBA EXTRACTS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES
IL201885A0 (en) Use of tp modulators for the treatment of cardiovascular disorders in aspirin sensitive and other populations
EP2340839A4 (en) COMPOSITION OF PLANT EXTRACTS AND THEIR USE IN THE PROPHYLAXIS OR TREATMENT OF METABOLISM DISORDERS OF BLOOD LIPIDES
IL197237A0 (en) Use of c7 sugars in prevention and treatment of mycoses
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
EP2240191A4 (en) COMPOSITION WITH LYSIMACHIA CLETHROIDES EXTRACTS FOR THE PREVENTION AND TREATMENT OF CARDIOVASIS DISEASES
EP1997487A4 (en) PRODUCT USED IN THE PREVENTION AND TREATMENT OF CARDIAC DISEASES, CANCER AND INFLAMMATORY DISEASES
ZA200904755B (en) Use of epothilones in the treatment of osteoporosis and related diseases
SI2182954T1 (sl) Uporaba nor-žolčnih kislin pri zdravljenju arterioskleroze
HK1185345A1 (zh) 用於預防和治療心血管疾病的化合物
DOP2008000082A (es) Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares.
ZA200808072B (en) Heterocyclic compounds and their use in the treatment of cardiovascular disease
AU2008101066A4 (en) The use of leeches in cardiovascular and vascular disease